0001213900-23-056621.txt : 20230713 0001213900-23-056621.hdr.sgml : 20230713 20230713090022 ACCESSION NUMBER: 0001213900-23-056621 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230711 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230713 DATE AS OF CHANGE: 20230713 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pluri Inc. CENTRAL INDEX KEY: 0001158780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 980351734 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31392 FILM NUMBER: 231085821 BUSINESS ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 BUSINESS PHONE: 972-74-710-7171 MAIL ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM THERAPEUTICS INC DATE OF NAME CHANGE: 20071228 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM LIFE SYSTEMS INC DATE OF NAME CHANGE: 20030701 FORMER COMPANY: FORMER CONFORMED NAME: AI SOFTWARE INC DATE OF NAME CHANGE: 20010906 8-K 1 ea181710-8k_pluri.htm CURRENT REPORT
0001158780 false 0001158780 2023-07-11 2023-07-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): July 13, 2023 (July 11, 2023)

 

PLURI INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   001-31392   98-0351734
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

MATAM Advanced Technology Park     
Building No. 5    
HaifaIsrael   3508409
(Address of Principal Executive Offices)   (Zip Code)

 

011 972 74 710 7171

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, par value $0.00001 per share   PLUR   The Nasdaq Global Market

  

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 11, 2023, the board of directors (the “Board”) of Pluri Inc. (the “Company”) appointed Mr. Lorne Abony to serve as a member of the Board, effective immediately, to hold office until the next meeting of shareholders of the Company at which directors are being elected or as set forth in the Company’s bylaws.

 

Mr. Abony, age 53, is an experienced entrepreneur who has decades of experience building and scaling multi-billion-dollar global businesses – both public and private companies – across multiple industries. He has served as a member of the board of directors of Yooma Wellness Inc. (CSE: YOOM), a company that markets, distributes and sells “wellness” products, including hemp seed oil and hemp-derived and cannabinoid products, since June 2020, of Einride AB, a freight technology company, since December 2021, of Amy Insights Inc., a company that simplifies sales performance tracking, since August 2022, and of VitroLabs Inc., a company that manufactures leather using stem cell-based technologies, since June 2023. Mr. Abony previously served as a member of the board of directors of Emmac Life Sciences Ltd., a medicinal cannabis company, from February 2018 to March 2021. Mr. Abony holds an MBA from Columbia Business School, New York and a J.D. from the University of Windsor, Canada.

 

Mr. Abony will be appointed to the Compensation Committee and the Audit Committee of the Board. As remuneration for his service as a director, Mr. Abony agreed to forego an annual cash fee and, in return, will receive options to purchase 100,000 common shares, par value $0.00001 per share, which shall vest quarterly over a one year period, at an exercise price of $0.76, under the Company’s 2016 Equity Compensation Plan (the “Plan”), in accordance with the terms of the Plan. Except as set forth herein, there are no arrangements or understandings between Mr. Abony and any other persons pursuant to which he was appointed as a member of the Board.

 

There are no family relationships between any of the Company’s directors or officers and Mr. Abony. There are no related party transactions involving Mr. Abony that are reportable under Item 404(a) of Regulation S-K.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PLURI INC.
   
Date: July 13, 2023 By:  /s/ Chen Franco-Yehuda
 

Name: 

Title:

Chen Franco-Yehuda
Chief Financial Officer

 

 

 

 

EX-101.SCH 2 plur-20230711.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 plur-20230711_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 plur-20230711_pre.xml XBRL PRESENTATION FILE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jul. 11, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 11, 2023
Entity File Number 001-31392
Entity Registrant Name PLURI INC.
Entity Central Index Key 0001158780
Entity Tax Identification Number 98-0351734
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One MATAM Advanced Technology Park
Entity Address, Address Line Two Building No. 5
Entity Address, City or Town Haifa
Entity Address, Country IL
Entity Address, Postal Zip Code 3508409
City Area Code 011
Local Phone Number 972 74 710 7171
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol PLUR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 ea181710-8k_pluri_htm.xml IDEA: XBRL DOCUMENT 0001158780 2023-07-11 2023-07-11 iso4217:USD shares iso4217:USD shares 0001158780 false 8-K 2023-07-11 PLURI INC. NV 001-31392 98-0351734 MATAM Advanced Technology Park Building No. 5 Haifa IL 3508409 011 972 74 710 7171 false false false false Common Stock, par value $0.00001 per share PLUR NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pluri-biotech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea181710-8k_pluri.htm plur-20230711.xsd plur-20230711_lab.xml plur-20230711_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea181710-8k_pluri.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea181710-8k_pluri.htm" ] }, "labelLink": { "local": [ "plur-20230711_lab.xml" ] }, "presentationLink": { "local": [ "plur-20230711_pre.xml" ] }, "schema": { "local": [ "plur-20230711.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PLUR", "nsuri": "http://pluri-biotech.com/20230711", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea181710-8k_pluri.htm", "contextRef": "From2023-07-11to2023-07-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://pluri-biotech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "ea181710-8k_pluri.htm", "contextRef": "From2023-07-11to2023-07-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001213900-23-056621-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-056621-xbrl.zip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end